AZRAzora Therapeutics, Inc. (DE)
Earnings
When Azora Therapeutics, Inc. (DE) reports, what it reported each quarter, and how the stock took the results.
38 quarters. Jun 30, 2017 to Sep 30, 2026. mixed units.
Next results · Q4 2026Projected
10-K due Mar 1 – Apr 2
No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 8 filings.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 1 – Apr 2
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Net income
- -$2.00M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- —
- —
- Net income
- -$64.56M
- N/M
- EPS
- -$4.52
- N/M
- Q2 2026Aug 14, 2026, after the close
- Revenue
- —
- —
- Net income
- -$51.99M
- N/M
- EPS
- -$11.25
- N/M
- Q1 2026May 8, 2026, after the close
- Revenue
- —
- —
- Net income
- -$2.02M
- N/M
- EPS
- -$1.48
- N/M
- Q4 2025Mar 5, 2026, after the close
- Revenue
- —
- —
- Net income
- -$2.00M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 12, 2026 · after-hours | Nov 12, 2026 | 43 d | 10-Q | — | — | -$4.52 | — | |
| Q2 2026 | Jun 30, 2026 | — | Aug 14, 2026 | 45 d | 10-Q | — | — | -$11.25 | — | |
| Q1 2026 | Mar 31, 2026 | — | May 8, 2026 | 38 d | 10-Q | — | — | -$1.48 | — | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | — | Mar 5, 2026 | 64 d | 10-K | — | — | — | — | |
| Q3 2025 | Sep 30, 2025 | — | Nov 13, 2025 | 44 d | 10-Q | — | — | -$2.02 | — | |
| Q2 2025 | Jun 30, 2025 | — | Aug 13, 2025 | 44 d | 10-Q | — | — | -$4.61 | — | |
| Q1 2025 | Mar 31, 2025 | — | May 14, 2025 | 44 d | 10-Q | — | — | -$8.52 | — | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Mar 4, 2025 · pre-market | Mar 4, 2025 | 63 d | 10-K | — | — | — | — | |
| Q3 2024 | Sep 30, 2024 | — | Nov 13, 2024 | 44 d | 10-Q | — | — | -$0.38 | — | |
| Q2 2024 | Jun 30, 2024 | — | Aug 13, 2024 | 44 d | 10-Q | — | — | -$0.59 | — | |
| Q1 2024 | Mar 31, 2024 | — | May 14, 2024 | 44 d | 10-Q | — | — | -$2.19 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | — | Apr 1, 2024 | 92 d | 10-K | — | — | — | — | |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 · after-hours | Nov 14, 2023 | 45 d | 10-Q | — | — | -$1.18 | — | |
| Q2 2023 | Jun 30, 2023 | Aug 21, 2023 · pre-market | Aug 21, 2023 | 52 d | 10-Q | — | — | $0.96 | — | |
| Q1 2023 | Mar 31, 2023 | May 12, 2023 · after-hours | May 12, 2023 | 42 d | 10-Q | — | — | -$0.11 | — | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | — | Mar 30, 2023 | 89 d | 10-K | — | — | — | — | |
| Q3 2022 | Sep 30, 2022 | — | Nov 14, 2022 | 45 d | 10-Q | — | — | -$3.02 | — | |
| Q2 2022 | Jun 30, 2022 | — | Aug 15, 2022 | 46 d | 10-Q | — | — | -$3.96 | — | |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 · pre-market | May 16, 2022 | 46 d | 10-Q | — | — | -$0.13 | — | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | — | Mar 28, 2022 | 87 d | 10-K | — | — | — | — | |
| Q3 2021 | Sep 30, 2021 | — | Nov 15, 2021 | 46 d | 10-Q | — | — | -$0.22 | — | |
| Q2 2021 | Jun 30, 2021 | — | Aug 12, 2021 | 43 d | 10-Q | — | — | -$0.25 | — | |
| Q1 2021 | Mar 31, 2021 | — | May 17, 2021 | 47 d | 10-Q | — | — | -$0.30 | — | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | — | Mar 22, 2021 | 81 d | 10-K | — | — | — | — | |
| Q3 2020 | Sep 30, 2020 | — | Nov 13, 2020 | 44 d | 10-Q | — | — | -$0.24 | — | |
| Q2 2020 | Jun 30, 2020 | — | Aug 13, 2020 | 44 d | 10-Q | — | — | -$0.16 | — | |
| Q1 2020 | Mar 31, 2020 | — | May 14, 2020 | 44 d | 10-Q | — | — | -$0.22 | — | |
| FY 2019 | ||||||||||
| Q4 2019derived | Dec 31, 2019 | — | Mar 20, 2020 | 80 d | 10-K | — | — | — | — | |
| Q3 2019 | Sep 30, 2019 | — | Nov 14, 2019 | 45 d | 10-Q | — | — | -$0.17 | — | |
| Q2 2019 | Jun 30, 2019 | — | Aug 13, 2019 | 44 d | 10-Q | — | — | -$0.21 | — | |
| Q1 2019 | Mar 31, 2019 | — | May 13, 2019 | 43 d | 10-Q | — | — | -$0.33 | — | |
| FY 2018 | ||||||||||
| Q4 2018derived | Dec 31, 2018 | — | Feb 19, 2019 | 50 d | 10-K | — | — | — | — | |
| Q3 2018 | Sep 30, 2018 | — | Nov 14, 2018 | 45 d | 10-Q | — | — | -$1.48 | — | |
| Q2 2018 | Jun 30, 2018 | — | Sep 10, 2018 | 72 d | 10-Q | — | — | -$0.50 | — | |
| Q1 2018 | Mar 31, 2018 | — | — | — | — | — | — | -$0.12 | — | |
| FY 2017 | ||||||||||
| Q4 2017derived | Dec 31, 2017 | — | — | — | — | — | — | — | — | |
| Q3 2017 | Sep 30, 2017 | — | — | — | — | — | — | -$0.09 | — | |
| Q2 2017 | Jun 30, 2017 | — | — | — | — | — | — | -$0.08 | — | |
Earlier years, FY 2017 to FY 2023The latest three years
Source filings
Provenance
ProvenanceData status and checks
Azora Therapeutics, Inc. (DE) · CIK 1513525 · Engraved from SEC EDGAR